Diabetic retinopathy: Pathogenesis, clinical grading, management and future developments

Diabetic Medicine

Volumn 30, Issue 6, 2013, Pages 640-650

  Heng, L Z ^a   Comyn, O ^a   Peto, T ^a   Tadros, C ^a   Ng, E ^b   Sivaprasad, S ^a   Hykin, P G ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b QUEEN S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AFLIBERCEPT; AKB 9778; ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; CANDESARTAN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; EYELEA; FIBRIC ACID DERIVATIVE; FLUOCINOLONE ACETONIDE; GLUCOSE; GLUTAMIC ACID; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LISINOPRIL; RANIBIZUMAB; RAPAMYCIN; RECOMBINANT GROWTH FACTOR; SULFONYLUREA; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARGON LASER; BLOOD PRESSURE REGULATION; CAPILLARY PERMEABILITY; CARDIOVASCULAR RISK; CATARACT; CLINICAL EXAMINATION; CLINICAL PRACTICE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; GENE EXPRESSION; GLAUCOMA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH PROGRAM; HEMOGLOBIN BLOOD LEVEL; HUMAN; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INTRAOCULAR PRESSURE; KALLIKREIN KININ SYSTEM; LASER COAGULATION; LOW LEVEL LASER THERAPY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PATIENT ASSESSMENT; PATIENT REFERRAL; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SLIT LAMP; TREATMENT OUTCOME; TREATMENT RESPONSE; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY;

ANIMALS; BIOMEDICAL RESEARCH; DIABETIC RETINOPATHY; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; HUMANS; MACULAR DEGENERATION; MASS SCREENING; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VITREORETINOPATHY, PROLIFERATIVE;

EID: 84878036026     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12089     Document Type: Review

References (47)

1. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35: 556-564.
2. Arden GB, Sivaprasad S. Hypoxia and oxidative stress in the causation of diabetic retinopathy. Curr Diabetes Rev 2011; 7: 291-304.
3. Arden GB, Sivaprasad S. The pathogenesis of early retinal changes of diabetic retinopathy. Doc Ophthalmol 2012; 124: 15-26.
4. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012; 366: 1227-1239.
5. Kleinman ME, Baffi JZ, Ambati J. The multifactorial nature of retinal vascular disease. Ophthalmologica 2010; 224 Suppl 1: 16-24.
6. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. Faseb J 2004; 18: 1450-1452.
7. Flaxel CJ, Edwards AR, Aiello LP, Arrigg PG, Beck RW, Bressler NM et al. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network. Retina 2010; 30: 1488-1495.
8. NHS Screening Programmes. Changes to common pathway to be implemented by local diabetic eye screening programmes by April 2013. 2012. Available at http://diabeticeye.screening.nhs.uk/pathway Last accessed 10 September 2012.
9. NHS Screening Programmes. Policy on Grading Criteria and Actions in the NHS Diabetic Eye Screening Programme. 2012. Available at http://diabeticeye.screening.nhs.uk/pathway Last accessed 10 September 2012.
10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
11. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
12. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342: 381-389.
13. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
14. Goh SY, Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143-1152.
15. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713.
16. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-1576.
17. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.
18. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51.
19. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394-1402.
20. Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 372: 1385-1393.
21. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
22. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
23. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-244.
24. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796-1806.
25. Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127: 245-251.
26. Bressler SB, Diabetic Retinopathy Clinical Research Network. Green Or Yellow Laser For Diabetic Macular Edema [ARVO Abstract]. Invest Ophthalmol Vis Sci 2012; 53: 5277.
27. Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol 2009; 93: 1341-1344.
28. Vujosevic S, Bottega E, Casciano M, Pilotto E, Convento E, Midena E. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina 2010; 30: 908-916.
29. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J et al. Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema. Ophthalmology 2012; 119: 2125-2132.
30. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
31. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.
32. Mitchell P, RESTORE extension study group. 2-year Safety And Efficacy Outcome Of Ranibizumab 0.5 mg In Patients With Visual Impairment Due To Diabetic Macular Edema (DME): An Interim Analysis Of The Restore Extension Study [ARVO Abstract]. Invest Ophthalmol Vis Sci 2012; 53: 4667.
33. Mitchell P. Three-Year Safety and Efficacy of Ranibizumab in Patients With Visual Impairment Due to Diabetic Macular Edema: The RESTORE Extension Study [American Academy of Ophthalmology Abstract]. 2012:532.
34. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077 e35.
35. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801.
36. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F et al. A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study)12-Month Data: Report 2. Ophthalmology 2010; 117: 1078-1086 e2.
37. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012; 130: 972-979.
38. Michaelides M, Fraser-Bell S, Hamilton R, Kaines A, Egan C, Bunce C et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina 2010; 30: 781-786.
39. Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ et al. The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema. Ophthalmology 2011; 118: 1819-1826.
40. Bressler NM, Boyer DS, Williams DF, Butler S, Francom SF, Brown B et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina 2012; 32: 1821-1828.
41. Campbell RJ, Gill SS, Bronskill SE, Paterson JM, Whitehead M, Bell CM. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ 2012; 345: e4203.
42. Dugel PU, Blumenkranz MS, Haller JA, Williams GA, Solley WA, Kleinman DM et al. A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. Ophthalmology 2012; 119: 124-131.
43. Chen YD, Xu X, Xia X, Wu H, Liu K, Zheng Z et al. MMP9 is involved in glycation end-products induced increase of retinal vascular permeability in rats and the therapeutic effect of minocycline. Curr Eye Res 2008; 33: 977-983.
44. Pruneau D, Belichard P, Sahel JA, Combal JP. Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy. Curr Opin Investig Drugs 2010; 11: 507-514.
45. Mohammad G, Kowluru RA. Diabetic retinopathy and signaling mechanism for activation of matrix metalloproteinase-9. J Cell Physiol 2012; 227: 1052-1061.
46. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981; 88: 583-600.
47. Velez-Montoya R, Guerrero-Naranjo JL, Gonzalez-Mijares CC, Fromow-Guerra J, Marcellino GR, Quiroz-Mercado H et al. Pattern scan laser photocoagulation: safety and complications, experience after 1301 consecutive cases. The British journal of ophthalmology 2010; 94: 720-724.